

# Frankie Ann Holmes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1611865/publications.pdf>

Version: 2024-02-01

14  
papers

133  
citations

1937685

4  
h-index

1474206

9  
g-index

14  
all docs

14  
docs citations

14  
times ranked

260  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. <i>Clinical Cancer Research</i> , 2015, 21, 4305-4311.	7.0	51
2	Effects of HER Family-Targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 807-818.	7.0	34
3	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6149-6157.	7.0	29
4	Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2019, 5, 36.	5.2	9
5	Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1017-1017.	1.6	3
6	Five-year results of a phase III trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (with trastuzumab in Tumor-Overlock 10 Trial) in breast cancer. <i>Cancer Medicine</i> , 2018, 7, 2288-2298.	2.8	2
7	Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial. <i>Cancer Research</i> , 2021, 81, PD3-03-PD3-03.	0.9	2
8	Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100033.	0.1	1
9	Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.. <i>Journal of Clinical Oncology</i> , 2012, 30, 547-547.	1.6	1
10	Abstract P2-13-21: Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial. <i>Cancer Research</i> , 2022, 82, P2-13-21-P2-13-21.	0.9	1
11	Scalp cooling alopecia prevention trial (SCALP).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9660-TPS9660.	1.6	0
12	Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative anti-HER2 therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 625-625.	1.6	0
13	HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 621-621.	1.6	0
14	Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS10144-TPS10144.	1.6	0